ERBB2 and breast cancer: We analyzed pre‐NAT tumor biopsies from TNBC, HR+, and HER2+ breast cancer patients who received NAT and compared the different immune makers (PD‐1, PD‐L1, CD3, and CD8) of tumor‐infiltrating lymphocytes (TILs).